The clinical significance of and prospects for the use of biopolymer-based microheterogeneous collagen-containing injectable hydrogel in the therapy of osteoarthritis

The paper gives the current definition of osteoarthritis (OA), which reflects the pathogenetic and clinical characteristics of this disease, as well as general principles for choosing an OA treatment. It describes the effect of glucosamine and chondroitin on the key pathogenetic mechanisms of OA. It is noted that one of the promising areas of therapy for OA is the intra-articular administration of biopolymer-based hydrogels that provide not only an anti-inflammatory, but also regenerative effect that has been experimentally confirmed during their injection into the tendon sheaths.
There are data on the efficacy and safety of the Russian drug Sphero®gel, a biopolymer-based microheterogeneous collagen-containing hydrogel that belongs to a class of multicomponent biopolymer-based extracellular matrix mimetics. It consists of the cross-linked farm animal tissue-derived collagen microparticles placed in the gel base. The gel is not only a structural base for collagen microparticles; it also has its own therapeutic potential, since it is structurally similar to the natural extracellular matrix. The drug contains collagen, biologically active components of the extracellular matrix, such as proteoglycans, glycoproteins, uronic acids, growth factors, monosaccharides, and chondroitin sulfate. Extended-release symptomatic agents, Sphero®gel among them, are currently recommended for the treatment of OA. Application of Sphero®gel contributes to increased joint mobility and reduced pain, which allows the limited use of nonsteroidal anti-inflammatory drugs that cause adverse reactions, especially in the presence of comorbid diseases.

musculoskeletal system diseases, knee osteoarthritis, injectable formulations for osteoarthritis treatment, biopolymer-based heterogeneous hydrogels for osteoarthritis treatment, Sphero®gel

1. Galushko EA, Bol'shakova TV, Vinogradova IB, et al. Structure of rheumatic diseases among adult population of Russia according to data of an epidemiological study (preliminary results). Nauchno-prakticheskaya revmatologiya. 2009;47(1):11–7. (In Russ.)

2. Guccione AA, Felson DT, Anderson JJ, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health. 1994 Mar;84(3):351-8. doi: 10.2105/ajph.84.3.351.

3. Balabanova RM, Erdes ShF. Trends inthe prevalence of rheumatic diseases in ICD-10 in the adult population of the Russian Federation over 2000-2010. Nauchno-prakticheskaya revmatologiya. 2012;50(3): 10-2. (In Russ.)

4. Balabanova RM, Dubinina TV, Demina AB, Krichevskaya OA. Incidence of diseases of the musculoskeletal system in the Russian Federation in 2015-2016. Nauchno-prakticheksaya revmatologiya. 2018;56(1):15-21. (In Russ.)

5. Standardization of Osteoarthritis Definitions, Osteoarthritis Research Society International. https://www.oarsi.org/research/standardizationosteoarthritis-definitions.

6. Yakhno NN, Kukushkin ML, editors. Bol’ (prakticheskoe rukovodstvo dlya vrachei) [Pain (a practical guide for doctors)]. Moscow: Izdatel'stvo RAMN; 2012. 512 p.

7. Bruyere O, Cooper C, Pelletier J, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi: 10.1016/j.semarthrit.2014.05.014. Epub 2014 May 14.

8. Denisov LN, Tsvetkova ES, Golubev GSh, et al. Algorithm for the treatment of knee osteoarthritis of the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Applicable in Russian clinical practice: joint conclusion of leading Russian specialists and experts (ESCEO) on osteoarthritis. Nauchno-prakticheskaya revmatologiya. 2016;54(6):641-53. (In Russ.)

9. Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec; 49(3):337-50. doi:10.1016/j.semarthrit.2019. 04.008. Epub 2019 Apr 30.

10. Leopoldino AO, Machado GC, Ferreira PH, et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst Rev. 2019 Feb 25;2(2):CD013273. doi: 10.1002/14651858.CD013273.

11. Engles CD, Hauser PJ, Abdullah SN, et al. Intravesical chondroitin sulfate inhibits recruitment of inflammatory cells in an acute acid damage «leaky bladder» model of cystitis. Urology. 2012 Feb;79(2):483.e13-7. doi: 10.1016/j.urology.2011.10.010. Epub 2011 Dec 2.

12. Hardingham TE. Chondroitin sulfate and joint disease. Osteoarthritis Cartilage. 1998 May;6 Suppl A:3-5. doi: 10.1016/s1063-4584(98)80004-6.

13. Tat SK, Pelletier JP, Verges J, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Res Ther. 2007;9(6):R117. doi: 10.1186/ar2325.

14. Alekseeva LI. Pharmacotherapy of osteoarthritis: the role and place of chondroitin sulfate. Trudnyi patsient. 2007;(5): 43-7. (In Russ.)

15. Largo R, Sanches-Pernaute O, MorenoRubio J, et al. Chondroitin sulfate prevents synovial inflammation in an experimental model of chronic arthritis, which might be mediated by the inhibition of the NF-κB dependent pathway. Osteoarthritis Cartilage. 2008;16(suppl 4):28-9. doi: 10.1016/S1063-4584(08)60081-3

16. Hamerman D. The biology of osteoarthritis. N Engl J Med. 1989 May 18;320(20): 1322-30. doi: 10.1056/NEJM198905183202006.

17. Rovati LC, Girolami F, Persiani S. Crystalline glucosamine sulfate in the maagement of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis. 2012 Jun;4(3):167-80. doi: 10.1177/1759720X12437753.

18. Kucharz EJ, Kovalenko V, Szanto S, et al. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin. 2016 Jun;32(6):997-1004. doi: 10.1185/03007995.2016.1154521. Epub 2016 Feb 26.

19. Reginster JY, Neuprez A, Lecart MP, et al. Role of glucosamine in the treatment for osteoarthritis. Rheumatol Int. 2012 Oct; 32(10):2959-67. doi: 10.1007/s00296-012-2416-2. Epub 2012 Mar 30.

20. Largo R, Alvarez-Soria MA, DТezOrtego I, et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 2003 Apr;11(4):290-8. doi: 10.1016/s1063-4584(03)00028-1.

21. Gouze JN, Bianchi A, BОcuwe P, et al. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-kappa B pathway. FEBS Lett. 2002 Jan 16;510(3):166-70. doi: 10.1016/s0014-5793(01)03255-0.

22. Chan PS, Caron JP, Rosa GJ, Orth MW. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage. 2005 May; 13(5):387-94. doi: 10.1016/j.joca.2005.01.003.

23. Taniguchi S, Ryu J, Seki M, et al. Longterm oral administration of glucosamine or chondroitin sulfate reduces destruction of cartilage and up-regulation of MMP-3 mRNA in a model of spontaneous osteoarthritis in Hartley guinea pigs. J Orthop Res. 2012 May;30(5):673-8. doi: 10.1002/jor.22003. Epub 2011 Nov 4.

24. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020 Feb;72(2):149-62. doi: 10.1002/acr.24131. Epub 2020 Jan 6.

25. Dydykina IS, Nurbaeva KS, Kovalenko PS, Zotkin EG. Diseases of musculoskeletal system: a rationale for possibility of inclusion of undenatured type II collagen into complex therapy of knee ostheoartritis. Terapiya. 2019; (6):190-7. (In Russ.)

26. Wehling P, Evans C, Wehling J, Maixner W. Effectiveness of intra-articular therapies in osteoarthritis: a literature review. Ther Adv Musculoskelet Dis. 2017 Aug;9(8):183-96. doi: 10.1177/1759720X17712695. Epub 2017 Jun 20.

27. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov;27(11):1578-89. doi: 10.1016/j.joca. 2019.06.011. Epub 2019 Jul 3.

28. Sevast'yanov VI. Technologies of tissue engineering and regenerative medicine. Vestnik transplantologii i iskusstvennykh organov. 2014;16(3):93-108. (In Russ.)

29. Nikitin AA, Tarasov IV, Perova NV, et al. Modern methods of minimally invasive treatment of arthrosis of the temporomandibular joint. Vestnik sovremennoi klinicheskoi meditsiny. 2016;9(4):89-96. (In Russ.)

30. Minasov BSh, Ginoyan AO, Saubanov RA, et al. Efficacy of structure-modifying therapy in patients with osteoarthrtitis of knee-joint in a subacute period. Opinion Leader. 2019;(29):43-8. (In Russ.)

31. Sevast'yanov VI, Perova NV, Saikovskii RS, Solov'eva IV. Primenenie in"ektsionnykh form biopolimernykh geterogennykh gidrogelei pri degenerativno-distroficheskikh porazheniyakh sustavov: prakticheskoe posobie dlya vrachei [Application of injectable forms of biopolymer heterogenic hydrogels in degenerativedystrophic damage of joints: practical guide for doctors]. Moscow: Triada; 2012

32. Solov'eva IV, Perova NV, Sevast'yanov VI. Applications of biopolymer microheterogeneous collagen contained gel in injuries and diseases of the musculoskeletal system. Sovremennaya meditsina. 2016;(2):66-9. (In Russ.)

33. Surguchenko VA, Ponomareva AS, Kirsanova LA, et al. Formation of tissueengineered construct of cartilage in vitro. Vestnik transplantologii i iskusstvennykh organov. 2013;15(3):66–72. (In Russ.)

34. Furuzawa-Carballeda J, MunozChable OA, Barrios-Payan J, HernandezPando R. Effect of polymerized-type I collagen in knee osteoarthritis. I. In vitro study. Eur J Clin Invest. 2009 Jul;39(7):591-7. doi: 10.1111/j.1365-2362.2009.02154.x.

35. Saikovskii RS, Savenkova NA, Aver'yanov AV, Lisitsa AV. The effectiveness of Spherogel in the treatment of knee osteoarthritis. Klinicheskaya praktika. 2013;(3):4-10. (In Russ.)

36. Solov'eva IV, Shesternya NA, Perova NV, Sevast'yanov VI. Coadministration of heterogeneous biopolymer hydrogel and hyaluronic acid in osteoarthritis: the first experience. Vrach. 2016;(1):12-7. (In Russ.)

37. https://spherogel.files.wordpress.com/2017/01/d0bad0bbd0b8d0bdd0b8d187d0b5d1 81d0bad0b8d0b5-d0b8d181d181d0bbd0b 5d0b4d0bed0b2d0b0d0bdd0b8d18fd182d180d0bed0b8d186d0ba.pdf

38. Tarasov IV, Nikitin AA, Perova NV, et al. Conservative treatment of arthrosis of the temporomandibular joint. Vestnik sovremennoi klinicheskoi meditsiny. 2016;9(4):66-71. (In Russ.)

39. Strakhov MA, Zagorodnii NV, Egiazaryan KA, et al. Experience in treating a patient with bilateral aseptic necrosis of the femoral head with bioimplant Sfero®gel. Clinical case. Sovremennaya meditsina. 2019;(2):26-30. (In Russ.)].